Avalo Therapeutics (AVTX) has raised $472 million, ensuring funding through 2029 to support its registrational-stage biotech development. The company’s lead drug, abdakibart, showed strong Phase II results for treating hidradenitis suppurativa, with significant efficacy and a clean safety profile in both biologic-experienced and naive patients. This financial strength reduces near-term dilution risk and boosts Avalo's leverage for upcoming Phase 3 trials and further pipeline development, including AVTX-010, which aims to improve dosing intervals and extend intellectual property protection. The company’s strategy targets a high-risk, differentiated market opportunity in hidradenitis suppurativa treatment.
VinFast Auto Ltd. is set to release its Q3 2026 earnings with analysts expecting a loss per share of $0.33 and revenues around $1.15 billion. The Vietnamese electric vehicle maker is expanding internationally, promoting its VF 9 SUV in Canada and ben...
United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a signi...
Oracle reported strong fiscal 2026 results with 17% revenue growth to $67 billion and a 36% net income increase, driven by a 75% surge in its cloud infrastructure segment. Despite a recent 55% stock price drop from its peak, Morgan Stanley raised Ora...
RBC Capital increased its price target for cybersecurity firm Zscaler to $210, maintaining an "Outperform" rating due to the company's strong financial results and AI innovation. Zscaler reported a 25% rise in revenue and Annual Recurring Revenue, su...
Cryptocurrency markets show mixed movements as Bitcoin trades near $79,224, down 1.86%, and Ethereum falls 1.59% to $2,450.47. While many coins like XRP, SOL, and DOGE experience declines, some assets such as ZEC and LIT see significant gains of 7.76...
